Skip to main content
Top
Published in: Pediatric Radiology 1/2012

01-01-2012 | Original Article

Fracture after bisphosphonate treatment in children with cerebral palsy: the role of stress risers

Authors: H. Theodore Harcke, Kimberly L. Stevenson, Heidi H. Kecskemethy, Steven J. Bachrach, Leslie E. Grissom

Published in: Pediatric Radiology | Issue 1/2012

Login to get access

Abstract

Background

In the nonambulatory cerebral palsy (CP) population with a prior history of fracture, the use of pamidronate is not always effective in preventing further fractures.

Objective

To test the hypothesis that when fractures occur after cyclic pamidronate, they will be at the proximal or distal end of a pamidronate band.

Materials and methods

Retrospective review of our CP patient database revealed 53 children who had received one or more complete courses of pamidronate therapy (five cycles over 12 months). Medical records were screened to identify children who had sustained a fracture or fractures after completing treatment.

Results

Of 53 patients treated with pamidronate, only 14 sustained fractures after treatment. Radiographs were available for 11 patients, showing 19 fractures. Sixty-three percent of these fractures were located at a junction with pamidronate bands but not within the bands.

Conclusions

We propose stress risers as the mechanism for fractures that have occurred where bone mineral density abruptly changes as a result of cyclic administration of pamidronate. We show a theoretical example of how alternative dosing might reduce the ratio and therefore decrease the chance of formation of a stress riser.
Literature
1.
go back to reference Bachrach SJ, Kecskemethy HH, Harcke HT et al (2010) Decreased fracture incidence after 1 year of pamidronate treatment in children with spastic quadriplegic cerebral palsy. Dev Med Child Neurol 52:837–842PubMedCrossRef Bachrach SJ, Kecskemethy HH, Harcke HT et al (2010) Decreased fracture incidence after 1 year of pamidronate treatment in children with spastic quadriplegic cerebral palsy. Dev Med Child Neurol 52:837–842PubMedCrossRef
2.
go back to reference Plotkin H, Bruzoni M, Coughlin S et al (2006) Low doses of pamidronate for the treatment of osteopenia in children with cerebral palsy. Dev Med Child Neurol 48:709–712PubMedCrossRef Plotkin H, Bruzoni M, Coughlin S et al (2006) Low doses of pamidronate for the treatment of osteopenia in children with cerebral palsy. Dev Med Child Neurol 48:709–712PubMedCrossRef
3.
go back to reference Bachrach SJ, Kecskemethy HH, Harcke HT et al (2006) Pamidronate treatment and post treatment bone density in children with spastic quadriplegic cerebral palsy. J Clin Densitom 9:167–174PubMedCrossRef Bachrach SJ, Kecskemethy HH, Harcke HT et al (2006) Pamidronate treatment and post treatment bone density in children with spastic quadriplegic cerebral palsy. J Clin Densitom 9:167–174PubMedCrossRef
4.
go back to reference Henderson RC, Lark RK, Kecskemethy HH et al (2002) Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr 141:644–651PubMedCrossRef Henderson RC, Lark RK, Kecskemethy HH et al (2002) Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr 141:644–651PubMedCrossRef
5.
go back to reference Shaw NJ, White CP, Fraser WD et al (1994) Osteopenia in cerebral palsy. Arch Dis Child 71:235–238PubMedCrossRef Shaw NJ, White CP, Fraser WD et al (1994) Osteopenia in cerebral palsy. Arch Dis Child 71:235–238PubMedCrossRef
6.
go back to reference Rauch F, Munns C, Land C et al (2006) Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. J Clin Endocrinol Metab 91:1268–1274PubMedCrossRef Rauch F, Munns C, Land C et al (2006) Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. J Clin Endocrinol Metab 91:1268–1274PubMedCrossRef
7.
go back to reference Marx RE, Sawatari Y, Fortin M et al (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575PubMedCrossRef Marx RE, Sawatari Y, Fortin M et al (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575PubMedCrossRef
8.
go back to reference Whyte MP, Wenkert D, Clements KL et al (2003) Bisphosphonate-induced osteopetrosis. N Engl J Med 349:457–463PubMedCrossRef Whyte MP, Wenkert D, Clements KL et al (2003) Bisphosphonate-induced osteopetrosis. N Engl J Med 349:457–463PubMedCrossRef
9.
go back to reference Grissom LE, Harcke HT (2003) Radiographic features of bisphosphonate therapy in pediatric patients. Pediatr Radiol 33:226–229PubMed Grissom LE, Harcke HT (2003) Radiographic features of bisphosphonate therapy in pediatric patients. Pediatr Radiol 33:226–229PubMed
10.
go back to reference Staheli L (2006) Practice of pediatric orthopedics, 2nd ed. Lipincott, Williams, and Wilkins, Philadelphia p 267 Staheli L (2006) Practice of pediatric orthopedics, 2nd ed. Lipincott, Williams, and Wilkins, Philadelphia p 267
11.
go back to reference Alford JW, Bradley MP, Fadale PD et al (2007) Resorbable fillers reduce stress risers from empty screw holes. J Trauma 63:647–654PubMedCrossRef Alford JW, Bradley MP, Fadale PD et al (2007) Resorbable fillers reduce stress risers from empty screw holes. J Trauma 63:647–654PubMedCrossRef
12.
go back to reference Miller F, Dabney KW, Rang M et al (1995) Complications in cerebral palsy treatment. In: Epps CH Jr, Bowen JR (eds) Complications in pediatric orthopaedic surgery. Lippincott, Philadelphia Miller F, Dabney KW, Rang M et al (1995) Complications in cerebral palsy treatment. In: Epps CH Jr, Bowen JR (eds) Complications in pediatric orthopaedic surgery. Lippincott, Philadelphia
13.
go back to reference Hernandez CJ (2008) How can bone turnover modify bone strength independent of bone mass? Bone 42:1014–1020PubMedCrossRef Hernandez CJ (2008) How can bone turnover modify bone strength independent of bone mass? Bone 42:1014–1020PubMedCrossRef
14.
go back to reference Andiran N, Alikasifoglu A, Gone N et al (2008) Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation. J Pediatr Endocrinol Metab 21:63–72PubMedCrossRef Andiran N, Alikasifoglu A, Gone N et al (2008) Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation. J Pediatr Endocrinol Metab 21:63–72PubMedCrossRef
15.
go back to reference Henderson RC, Lark RK, Newman JE et al (2002) Pediatric reference data for dual x-ray absorptiometric measures of bone density in the distal femur. AJR 178:439–443PubMed Henderson RC, Lark RK, Newman JE et al (2002) Pediatric reference data for dual x-ray absorptiometric measures of bone density in the distal femur. AJR 178:439–443PubMed
16.
go back to reference Zemel BS, Stallings VA, Leonard MB et al (2009) Revised pediatric reference data for the lateral distal femur measured by dual energy x-ray absorptiometry. J Clin Densitom 12:207–218PubMedCrossRef Zemel BS, Stallings VA, Leonard MB et al (2009) Revised pediatric reference data for the lateral distal femur measured by dual energy x-ray absorptiometry. J Clin Densitom 12:207–218PubMedCrossRef
17.
go back to reference Aspenberg P (2009) Bisphosphonates and fatigue fractures. IBMS BoneKEy 6:465–467CrossRef Aspenberg P (2009) Bisphosphonates and fatigue fractures. IBMS BoneKEy 6:465–467CrossRef
18.
go back to reference Neviaser AS, Lane JM, Lenart BA et al (2008) Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22:346–350PubMedCrossRef Neviaser AS, Lane JM, Lenart BA et al (2008) Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22:346–350PubMedCrossRef
19.
go back to reference Ing-Lorenzini K, Desmeules J, Plachta O et al (2009) Low-energy femoral fractures associated with the long-term use of bisphosphonates. Drug Saf 32:775–785PubMedCrossRef Ing-Lorenzini K, Desmeules J, Plachta O et al (2009) Low-energy femoral fractures associated with the long-term use of bisphosphonates. Drug Saf 32:775–785PubMedCrossRef
20.
go back to reference Bishop NE, Ferguson S, Tepic S (1996) Porosity reduction in bone cement at the cement-stem interface. J Bone Joint Surg 78B:349–356 Bishop NE, Ferguson S, Tepic S (1996) Porosity reduction in bone cement at the cement-stem interface. J Bone Joint Surg 78B:349–356
21.
go back to reference Rauch F, Cornibert S, Cheung M et al (2007) Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone 40:821–827PubMedCrossRef Rauch F, Cornibert S, Cheung M et al (2007) Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone 40:821–827PubMedCrossRef
22.
go back to reference Harcke HT, Taylor A, Bachrach S et al (1998) Lateral femoral scan: an alternative method for assessing bone mineral density in children with cerebral palsy. Pediatr Radiol 28:241–246PubMedCrossRef Harcke HT, Taylor A, Bachrach S et al (1998) Lateral femoral scan: an alternative method for assessing bone mineral density in children with cerebral palsy. Pediatr Radiol 28:241–246PubMedCrossRef
23.
go back to reference Ward KA, Adams JE, Freemont TJ et al (2007) Can bisphosphonate treatment be stopped in a growing child with skeletal fragility? Osteoporos Int 18:1137–1140PubMedCrossRef Ward KA, Adams JE, Freemont TJ et al (2007) Can bisphosphonate treatment be stopped in a growing child with skeletal fragility? Osteoporos Int 18:1137–1140PubMedCrossRef
24.
go back to reference Gandrud LM, Cheung JC, Daniels MW et al (2003) Low-dose intravenous pamidronate reduces fractures in childhood osteoporosis. J Pediatr Endocrinol Metabol 16:887–892CrossRef Gandrud LM, Cheung JC, Daniels MW et al (2003) Low-dose intravenous pamidronate reduces fractures in childhood osteoporosis. J Pediatr Endocrinol Metabol 16:887–892CrossRef
25.
go back to reference Steelman J, Zeitler P (2003) Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions. J Pediatr 142:417–423PubMedCrossRef Steelman J, Zeitler P (2003) Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions. J Pediatr 142:417–423PubMedCrossRef
Metadata
Title
Fracture after bisphosphonate treatment in children with cerebral palsy: the role of stress risers
Authors
H. Theodore Harcke
Kimberly L. Stevenson
Heidi H. Kecskemethy
Steven J. Bachrach
Leslie E. Grissom
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
Pediatric Radiology / Issue 1/2012
Print ISSN: 0301-0449
Electronic ISSN: 1432-1998
DOI
https://doi.org/10.1007/s00247-011-2198-9

Other articles of this Issue 1/2012

Pediatric Radiology 1/2012 Go to the issue